



FORM PTO-1449 (Modified)				Attorney Docket No.: 020093-001000US		Application No.: 10/009,508	
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)				Applicant: Sai L. SU			
				Filing Date: Nov. 6, 2001		Group: Not assigned	
Reference Designation				U.S. PATENT DOCUMENTS		Page 1 of 1	
Examiner Initial		Document No.	Date	Name	Class	Sub-class	Filing Date (If Appropriate)
FOREIGN PATENT DOCUMENTS							
		Document No.	Date	Country	Class	Sub-class	Translation (Yes/No)
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
82	AA	Achen <i>et al.</i> , "Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4)," <i>Proc. Natl. Acad. Sci. USA</i> 95:548-553 (1998)					
	AB	Bigler <i>et al.</i> , "Comparison of microscopic vascularity in benign and malignant prostate tissue," <i>Hum. Pathol.</i> 24:220-226 (1993)					
	AC	Brawer <i>et al.</i> , "Predictors of pathologic stage in prostatic carcinoma," <i>Cancer</i> 73:678-687 (1994)					
	AD	Brown <i>et al.</i> , "Vascular permeability factor (vascular endothelial growth factor) is strongly expressed in the normal male genital tract and is present in substantial quantities in semen," <i>J. Urol.</i> 154:576-579 (1995)					
	AE	Chevalier, "This month in investigative urology: Commentary on prostatic neovascularization and vascular endothelial growth factor," <i>J. Urol.</i> 157:2040-2041 (1997)					
	AF	Connolly <i>et al.</i> , "Angiogenesis in two human prostate cancer cell lines with differing metastatic potential when growing as solid tumors in nude mice," <i>J. Urol.</i> 160:932-936 (1998)					
	AG	Deering <i>et al.</i> , "Microvasculature in benign prostatic hyperplasia," <i>Prostate</i> 26:111-115 (1995)					
	AH	Ferrara <i>et al.</i> , "The vascular endothelial growth factor family of polypeptides," <i>J. Cell Biochem.</i> 47:211-8 (1991)					
	AI	Ferrara, "The role of vascular endothelial growth factor in pathological angiogenesis," <i>Breast Cancer Res. Treat.</i> 36:127-137 (1995)					
	AJ	Ferrer <i>et al.</i> , "Vascular endothelial growth factor (VEGF) expression in human prostate cancer: in situ and in vitro expression of VEGF by human prostate cancer cells," <i>J. Urol.</i> 157:2329-2333 (1997)					
	AK	Ferrer <i>et al.</i> , "Angiogenesis and prostate cancer: in vivo and in vitro expression of angiogenesis factors by prostate cancer cells," <i>Urology</i> 51:161-167 (1998)					
	AL	Frank <i>et al.</i> , "Regulation of vascular endothelial growth factor expression in cultured keratinocytes," <i>J. Biol. Chem.</i> 270:12607-12613 (1995)					
	AM	Furusato <i>et al.</i> , "Tumour angiogenesis in latent prostatic carcinoma," <i>Br. J. Cancer</i> 70:1244-1246 (1994)					
	AN	Galland <i>et al.</i> , "Chromosomal localization of <i>FLT4</i> , a Novel Receptor-Type Tyrosine Kinase Gene," <i>Genomics</i> 13:475-478 (1992)					
	AO	Gitay-Goren <i>et al.</i> , "Human melanoma cells but not normal melanocytes express vascular endothelial growth factor receptors," <i>Biochem. Biophys. Res. Commun.</i> 190:702-709 (1993)					
	AP	Harper <i>et al.</i> , "Vascular endothelial growth factor (VEGF) expression in prostatic tumours and its relationship to neuroendocrine cells," <i>Br. J. Cancer</i> 74:910-916 (1996)					
	AQ	Jackson <i>et al.</i> , "Vascular endothelial growth factor (VEGF) expression in prostate cancer and benign prostatic hyperplasia," <i>J. Urol.</i> 157:2323-2328 (1997)					
	AR	Jeltsch <i>et al.</i> , "Hyperplasia of lymphatic vessels in VEGF-C transgenic mice," <i>Science</i> 276:1423-1425 (1997)					
✓	AS	Joukov <i>et al.</i> , "A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases," <i>EMBO J.</i> 15:290-298 (1996)					

12 11/1/05



PTO/SB/08A (10-01)

Approved for use through 10/31/2002.OMB 0651-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.


Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete If Known	
				Application Number	10/009,508
				Filing Date	August 15, 2002
				First Named Inventor	Sai L. Su et al.
				Art Unit	TBA
				Examiner Name	TBA
Sheet	1	of	1	Attorney Docket Number	4280/0M988

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ³
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
SR	1	WO 95/27061A	10/12/95	Bennett et al.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See attached Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS						
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.				T ²
SR 	2	SU S L ET AL., Expression of vascular endothelial growth factor (VEGF), VEGF-C, and their receptors in prostate cancer (CaP)., Proceedings of the American Association for Cancer Research Annual, vol. 40, March 1999 (1999-03), page 614				
	3	ISRAELI R S ET AL., Sensitive nested reverse transcription polymerase chain reaction detection of circulating prostatic tumor cell: comparison of prostate-specific membrane antigen and prostate-specific antigen-based assays, Cancer Research, American Association for Cancer Research, Baltimore, MD, US, vol. 54, 15 December 1994, pages 6306-6310				
	4	MURPHY G P ET AL., Current evaluation of the tissue localization and diagnostic utility of prostate specific membrane antigen, Cancer, American Cancer Society, Philadelphia, PA, 1 December 1998, vol. 83, no. 11, pages 2259-2269				
	5	TSURUSAKI T ET AL., Vascular endothelial growth factor-c expression in human prostatic carcinoma and its relationship to lymph node metastasis, British Journal of Cancer, London, GB, April 1999, vol. 80, no ½, pages 309-313				
	6	Database EMBL, 1 May 1993, retrieved from EBI, accession no. X69878				

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	11/1/05
-----------------------	--	--------------------	---------

SEP 12 2003

PTO/SB/08a/b (08-03)

Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/009,508
				Filing Date	November 6, 2001
				First Named Inventor	Sai L. Su
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	1	of	1	Attorney Docket Number	04280/0M988US0

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
SR	AA	US-5,776,755-B1	07-07-1998	Alitalo et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
SR	BA	WO-WO 95/33772-A1	12-14-1995	Alitalo et al.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
SR	CA	Karamysheva, A.F. et al.: Expression of the FLT4/VEGFR3 receptor tyrosine kinase encoding gene in hepatic tumors, <i>International Journal of Oncology</i> , 25 April 1996, Vol. 8, No. 5, pages 921-924.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

(M:1428 010m99	Date Considered	11/1/05
-------------------	--------------------	---------